Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 701 - 750 out of 11,352

Document Document Title
WO/2021/068051A1
There is provided bombesin-derived compounds of Formula Ia (RX-L-Xaa1-Gln-Trp-Ala-Val-Xaa2-His-Xaa3-ψ-Xaa4-NH2). RX comprises a radionuclide chelator or a trifluoroborate-containing prosthetic group. L is a linker. Xaa1 is D-Phe, Cpa (4...  
WO/2021/061940A1
A bioartificial device, such as a bioartificial pancreas, for implantation in a patient's vascular system. The bioartificial pancreas includes a scaffold adapted to engage an interior wall of a blood vessel, a cellular complex support by...  
WO/2021/058758A1
The current invention relates to a cell composition comprising isolated mesenchymal stem cells, wherein said MSCs are radiolabeled with technetium-99m, wherein said radiolabel is essentially free of hexamethylpropylene amine oxime, and w...  
WO/2021/058549A1
The present disclosure relates to gastrin-releasing peptide receptor (GRPR) targeting pharmaceuticals and their use in a theragnostic approach for selection and therapy of subjects with GRPR-expressing malignancies. In particular, the pr...  
WO/2021/055350A1
Radiolabeled anti-MET antibodies and MET x MET bispecific antibodies and their use in immuno-PET imaging are provided herein. Included are methods of detecting the presence of MET proteins in a subject or sample and methods of monitoring...  
WO/2021/055638A1
Compositions and methods useful for the treatment of hemoglobinopathies and hematological diseases are disclosed herein. The compositions include an actinium-225 labeled anti-CD45 antibody (BC8) formulated as a single patient dose that i...  
WO/2021/052960A1
The present disclosure relates to radionuclide complex solutions of high concentration and of high chemical stability, that allows their use as drug product for diagnostic and/or therapeutic purposes. The stability of the drug product is...  
WO/2021/055641A1
Fibroblast activation protein (FAP)-targeting compounds (e.g., conjugates); a method for imaging cancer or fibrosis; and methods for treating an inflammatory disease/disorder and cancer.  
WO/2021/053040A1
The present invention relates to methods for radiolabelling GRPR antagonists such as NeoB, and their kits. In particular, the invention to a method for labeling a gastrin-releasing peptide receptor (GRPR) antagonist with a radioactive is...  
WO/2021/055575A1
Nanoparticles, methods, and kits are provided for supplying nutrients and other therapeutic agents to transplanted cells. Nutrient deprivation is a significant factor which contributes to poor outcome of many cell transplants because cel...  
WO/2021/055814A1
A method for detecting or ruling out non-small cell lung cancer (NSCLC) in a patient comprises: (a) administering to a patient a detectable amount of a compound of formula (I): Formula (I) wherein the compound is targeted to any NSCLC tu...  
WO/2021/051192A1
The present disclosure provides a composition that includes a mixture of (i) radioactive microparticles; and (ii) non-radioactive microparticles. The radioactive microparticles may be suitable to treat a vascularized tumour, such as a li...  
WO/2021/046653A1
Provided are antibodies that specifically bind Vaccinia Virus (VV) A56 or B5 antigen. Also provided are fusion proteins and conjugates that comprise the antibodies. Pharmaceutical compositions and kits that comprise the antibodies, fusio...  
WO/2021/046159A1
Provided are CD8 binding agents comprising a VHH domain that specifically binds human CD8. Also provided are nucleic acids encoding such CD8 binding agents, vectors comprising such nucleic acids, host cells comprising same, and methods o...  
WO/2021/046233A1
Provided herein are PMSA-binding molecules comprising a albumin-binding moiety and a chelating agent optionally chelating a therapeutic radioisotope or a PET-active, SPECT-active, or MR I -active radioisotope. The compound of Formula (II...  
WO/2021/046092A1
In one embodiment, the present application discloses compounds that are selective neuroactive agents for the treatment of diseases of the central nervous system (CNS). In one aspect, the neuroactive agents are compositions comprising Pol...  
WO/2021/038571A1
The present invention, in some embodiments thereof, is directed to an antigen binding polypeptide having increased binding affinity to prostate specific membrane antigen (PSMA). In some embodiments, the present invention is further direc...  
WO/2021/038596A1
Corticotropin releasing hormone peptide for positron emitting tomography imaging in Cushing's syndrome. The present invention discloses a composition for PET imaging in patients with Cushing's syndrome, to distinguish between Cushing's d...  
WO/2021/036022A1
A PET/CT tracer having selectivity for different lung cancer cells, a preparation method therefor and use thereof. The PET/CT tracer is a compound represented by formula I, or a salt or stereoisomer thereof, wherein R1 and R2 are each in...  
WO/2021/031930A1
Provided is a mutant of an antibody or fragment thereof, characterized in that the antibody or fragment thereof contains a light-chain constant region, and according to the Kabat numbering system, the amino acid at position 166 is mutate...  
WO/2021/034953A1
Compositions and methods for ablating CD206 expressing macrophages and/or CD206 expressing myeloid derived suppressor cells (MDSCs) are disclosed. In certain aspects, disclosed methods comprise administering to a subject in need thereof ...  
WO/2021/034943A1
Compositions and methods for in vivo immunoimaging IL-12 as a marker of IL- 12-producing activated antigen presenting cells (APCs) in a subject are provided according to aspects of the present disclosure which include: administering a la...  
WO/2021/034924A1
Featured are trans-cyclooctene and tetrazine compounds. Also provided are methods for evaluating the biodistribution and/or concentration of a biomolecule in a subject.  
WO/2021/032784A1
A compound comprising a bone-seeking agent capable of targeting bone of high metabolic activity (a pyrophosphate or a bisphosphonate) and a radiotoxic element (a Pt isotope, preferably 195mPt or 193mPt, more preferably 195mPt-isotope) is...  
WO/2021/026483A1
A new class of mass-tag polymers is provided, which include enriched metal isotopes such as zirconium and hafnium mass tags. The chemistry of these new mass tags are different from that of lanthanide mass tags, and opens up new mass chan...  
WO/2021/025984A1
Disclosed herein are compounds having a structure according to Formula I and optionally Formula IV. Formula I Formula IV. The compounds may be radiolabeled compounds useful for diagnosis and/or imaging fungal infections. In such embodime...  
WO/2021/019983A1
The purpose of the present invention is to react radioactive zirconium at a high reaction rate to synthesize a zirconium complex even using low-concentration DOTA or NOTA. A mixed solution, obtained by finally mixing zirconium dissolved ...  
WO/2021/015336A1
The present invention relates to a single domain antibody targeting αvβ3 integrin and various applications thereof. The single domain antibody targeting αvβ3 integrin of the present invention exhibits high avidity for αvβ3 integrin...  
WO/2021/013978A1
A compound of general formula (I): wherein: n is 1, 2 or 3; R1, R2, R3 and R4, independently represent OH or Q; and 20 Q represents a tissue-targeting moeity selected from the group consisting of or a stereoisomer, a hydrate, a solvate, ...  
WO/2021/013903A1
Triazolo[4,5-d]pyrimidine derivatives of formula (I) for use in prognosis and/or diagnosis of bacterial infection in a host mammal and method of imaging thereof. Formula (I) wherein R1 is C3-5 alkyl optionally substituted by one or more ...  
WO/2021/014103A1
The present invention concerns a particulate structure characterised in that it comprises: a/ a biodegradable polymer particle, b/ gold nanoparticles covered on their surface with macrocyclic chelators complexing at least one ion of inte...  
WO/2021/009047A1
The present invention relates to antibodies which bind to antigens on target cells and which target radionuclides to said cells, and to methods of using the same.  
WO/2021/011660A1
Disclosed herein are methods for detecting whether a subject is at risk of lung cancer based on a blood-based multivariate gene expression classifier. Methods for determining whether to obtain a biopsy in a subject based on a blood-based...  
WO/2021/008454A1
The present application relates to the technical field of biological medicine. In particular, the present application relates to a ferritin heavy chain subunit-based drug carrier. More specifically, the present application relates to a m...  
WO/2021/005630A1
The present invention relates to a radiopharmaceutical compound or composition for Positron Emission Tomography (PET) imaging of interleukin-2 (IL2) receptor positive cells, in particular, 68Ga-radiolabelled interleukin-2 such as a desal...  
WO/2021/002481A1
The purpose of the present invention is to provide a drug delivery carrier which can be accumulated selectively in the kidney in vivo and which can show high biodegrability and drug-release capability in the kidney. The present invention...  
WO/2021/001360A1
The present disclosure relates to prostate specific membrane antigen (PSMA) ligands. In particular, the disclosure relates to PSMA ligands having a glutamate-urea-lysine (GUL) moiety and a chelating agent that can comprise a radiometal. ...  
WO/2021/002994A1
A method of preparing a radioactive yttrium salt particle suspension comprising multiple steps comprising: using a hydrothermal process wherein a solution of soluble yttrium salt, from the group of yttrium chloride, yttrium nitrate, yttr...  
WO/2021/001362A1
The present disclosure relates to prostate specific membrane antigen (PSMA) ligands. In particular, the disclosure relates to PSMA ligands having a glutamate-urea- lysine (GUL) moiety, a radioisotope and a chelating agent that can compri...  
WO/2021/000018A1
The invention relates to anti-PSMA antibodies comprising a heavy chain constant region comprising one or more amino acid substitutions compared to a wild-type IgG, wherein the one or more amino acid substitutions reduce the affinity of t...  
WO/2021/000017A1
The invention relates to anti-CAIX antibodies comprising a heavy chain constant region comprising one or more amino acid substitutions compared to a wild-type IgG, wherein the one or more amino acid substitutions reduce the affinity of t...  
WO/2020/264307A1
A probe for positron emission tomography (PET) is disclosed. The probe is selected from the group consisting of yersiniabactin (Ybt) labeled with Copper-64; staphylopine (StP) labeled with Copper-64; yersiniabactin (Ybt) labeled with Zir...  
WO/2020/253824A1
The present invention belongs to the technical field of radiopharmaceutical chemistry, and provided are 18F-labeled fluoropicolinylglycine as well as a preparation method therefor and an application thereof. The 18F-labeled fluoropicolin...  
WO/2020/257409A1
A composition comprising including a homogeneous tin- 117m colloid comprising tin- 117m, and an ascorbic acid is provided, the composition naturally has a white coloration. The composition is visually distinct from a conventional homogen...  
WO/2020/254548A1
The invention comprises radiolabeled MOEM type oligonucleotide of the formula (I), (I) wherein n, X1, X2, the linker (1), the linker (2), Q* and the receptor targeting moiety are as defined (I) the description. The radiolabeled oligonucl...  
WO/2020/252598A1
A compound comprising a prostate specific membrane antigen (PSMA)-targeting moiety of the following formula or of a salt or a solvate thereof. R0 is O or S. Each of R1a, R1b and R1c may be –CO2H, –SO2H, –SO3H, –PO2H, or –PO3H2,...  
WO/2020/256545A1
Disclosed herein are compounds comprising trans-cyclooctene moieties, combinations, and kits that can be used to more quickly remove radionuclides from a subject, preferably a human being. Said compounds, combinations and kits can also b...  
WO/2020/257690A1
A unique pipeline is employed for biomarker discovery that entailed domain antibody phage display, next generation sequencing analysis, and nanotechnology strategies to generate antibody mimetics are disclosed. Also disclosed are the tem...  
WO/2020/257720A1
The present invention provides method of treating diseases, disorders and conditions in a human subject comprising administering to the subject a population of exosomes or a composition comprising a population of exosomes, wherein said p...  
WO/2020/254934A1
The method for the preparation of lipid nanoparticles, comprises: the phase of mixing in a single container a mixture comprising an aqueous solution with a solid lipid matrix and with at least one biocompatible non-ionic surfactant; the ...  

Matches 701 - 750 out of 11,352